Measure released doses delivered on time
Manufacturing yield compounds across upstream production, purification, formulation, fill-finish, testing, and distribution. A bottleneck at any one stage can idle the rest.
How much of the bulk actually becomes an administered dose?
Four yield stages multiply, not add. A single weak stage can undo strong performance everywhere else, which is why the article treats manufacturing capacity as a network, not one bottleneck to fix.
84% of bulk-equivalent doses ultimately reach a patient
- After drug substance
- 920
- After fill-finish
- 883
- After release testing
- 866
- After delivery & cold chain
- 840
Fill-finish reject rates in published industry data average around 2% for cosmetic defects alone, before adding filter holdup, overfill design margins, and formulation loss, the fill-finish slider bundles these into one illustrative stage yield. Move any single slider down and watch how much of the final total it removes, regardless of how strong the other three stages are.
Calculation and boundaries
Delivered doses per 1,000 bulk-equivalent doses started = 1,000 × drug-substance yield × fill-finish yield × release-testing pass rate × delivery/cold-chain completion, each expressed as a fraction. Stage yields are illustrative, order-of-magnitude ranges informed by public fill-finish loss literature, not audited figures for any specific product or manufacturer. Excludes demand shaping, procurement timing, and administration wastage after delivery.
Four stages, each with its own failure mode
A recipe that works at bench scale still has to survive supply, biology, sterility, and logistics before it reaches anyone.
Platform and inputs
Cell banks, plasmids, enzymes, lipids, media, vials, stoppers, and single-use systems establish the recipe and supply base.
- Measure
- Qualified suppliers · lead time
- Failure boundary
- A single specialized input shortage can stall an otherwise ready facility.
Where the frontier moves
Diversified, pre-qualified supplier networks that survive a single-source disruption.
Drug substance
Culture, synthesis, harvest, purification, and concentration create active material.
- Measure
- Yield · batch success
- Failure boundary
- Biological variability means even a validated process can produce a failed batch.
Where the frontier moves
Tighter process control and analytics that catch failures earlier and cheaper.
Drug product
Formulation, sterile filtration, filling, inspection, labeling, and packaging create doses.
- Measure
- Doses/hour · rejects
- Failure boundary
- Aseptic capacity is expensive, slow to build, and unforgiving of contamination.
Where the frontier moves
Higher-throughput fill lines and inspection systems that cut loss without cutting sterility assurance.
Release and delivery
Potency, sterility, stability, regulation, procurement, cold chain, and administration complete supply.
- Measure
- Released doses on time
- Failure boundary
- Testing and last-mile logistics can make physical production faster than usable supply.
Where the frontier moves
Expanded release-lab capacity and cold-chain infrastructure that keep pace with reactors.
Sterility and potency require evidence for every process
Biological products cannot be defined only by a chemical formula. Process control and validated assays demonstrate identity, purity, potency, and safety, imposing time and sampling even when equipment is fast.
Emergency expansion moves into peacetime sustainability
New regional capacity survives only with products, procurement commitments, workforce, maintenance, quality maturity, and supply networks during ordinary years.
Platform facilities
Reuse equipment, analytics, and trained teams across related products instead of building single-purpose plants.
Diversify critical inputs
Qualify multiple suppliers before shortages force last-minute process changes.
Strengthen release labs
Expand reference standards and testing capacity alongside reactors, not after them.
Shape demand
Use pooled procurement and advance commitments to support viable production between emergencies.
Who is building what
In vitro transcription, microfluidic lipid nanoparticle assembly, continuous bioreactors, and lot-release assays set the vaccine delivery clock. Search the record, or filter by manufacturing stage.
ModernamRNA Platform & Norwood FacilityIn vitro transcription of N1-methylpseudouridine modified mRNA, proprietary ionizable lipid formulation, and automated clinical manufacturing
- Reported evidence
- Delivered over 1 billion Spikevax doses; launched mRESVIA (RSV) using the same modular mRNA-LNP manufacturing architecture.
- Announced next step
- Combination respiratory vaccines (flu/COVID/RSV) and individualized neoantigen cancer therapies from automated pipelines.
- Unresolved risk
- Post-translational stability of mRNA constructs, cold-chain logistics (-20°C to -50°C), and patent litigation over lipid chemistries.
BioNTech / PfizerProject Lightspeed & BioNTainerHigh-speed mRNA synthesis, multi-site continuous lipid encapsulation, and modular shipping-container factories (BioNTainers) for regional production
- Reported evidence
- Manufactured and distributed over 4 billion doses of Comirnaty globally; established BioNTainer manufacturing site in Kigali, Rwanda.
- Announced next step
- Decentralized localized vaccine manufacturing across Africa and Latin America, advancing clinical oncology pipelines.
- Unresolved risk
- Maintaining cleanroom aseptic standards in modular facilities and technology transfer training for complex bioprocesses.
Precision NanoSystems (Cytiva)NanoAssemblr PlatformMicrofluidic laminar flow mixing architectures ensuring reproducible nanoparticle size, encapsulation efficiency, and batch-to-batch uniformity
- Reported evidence
- System in routine use across biopharmaceutical companies and academic labs for clinical-stage RNA-LNP drug formulation.
- Announced next step
- Continuous high-throughput microfluidic mixers capable of formulating dozens of liters per hour at GMP scale.
- Unresolved risk
- Channel fouling during continuous lipid precipitation and shear stress impacts on large fragile RNA molecules.
LonzaIbex SolutionsModular bioprocessing suites providing complete end-to-end drug substance synthesis, purification, and sterile fill-finish
- Reported evidence
- Manufactured hundreds of millions of bulk mRNA vaccine doses for Moderna from Visp, Switzerland and Portsmouth, New Hampshire.
- Announced next step
- Single-use continuous bioprocessing suites reducing cleanroom changeover time between different vaccine candidates.
- Unresolved risk
- Supply chain dependencies on raw consumables (sterile single-use bags, custom chromatography resins, capping enzymes).
National ResilienceContinuous BiomanufacturingAdvanced biomanufacturing network modernizing cell and gene therapy, viral vectors, and nucleic acid production with automated analytics
- Reported evidence
- Acquired and expanded multi-facility biopharma footprint across North America; secured BARDA and Department of Defense manufacturing contracts.
- Announced next step
- End-to-end pandemic readiness platform delivering release-ready doses within weeks of viral sequencing.
- Unresolved risk
- High capital depreciation on idle standby capacity during inter-pandemic periods.
CureVacThe RNA PrinterAutomated, closed-system benchtop mRNA printing designed to synthesize, formulate, and package formulated mRNA with minimal human intervention
- Reported evidence
- Developed portable RNA Printer prototypes; partnered with GSK on second-generation unmodified and modified mRNA vaccines.
- Announced next step
- Distributed point-of-care vaccine and personalized cancer immunotherapy manufacturing in hospitals and clinics.
- Unresolved risk
- Automated lot-release testing without manual analytical chemistry assays, and regulatory approval of decentralized release.
Sanofi / GSKRecombinant Protein & AS03Baculovirus expression vector systems in insect cells producing recombinant spike proteins, combined with squalene-based AS03 adjuvant
- Reported evidence
- Approved COVID-19 booster VidPrevtyn Beta; large-scale global manufacturing network for seasonal influenza vaccines.
- Announced next step
- Next-generation adjuvanted protein vaccines offering broader variant cross-protection and standard refrigerated (+4°C) stability.
- Unresolved risk
- Longer development lead times (6–9 months from sequence to batch) compared to days for synthetic mRNA.
CEPI100 Days MissionCoalition funding clinical prototypes, pre-clinical antigen libraries for 25+ viral families, and a global distributed manufacturing network
- Reported evidence
- Funded early-stage development of multiple leading COVID-19 vaccines and established clinical trial networks across low- and middle-income countries.
- Announced next step
- Developing and releasing safe, effective vaccines within 100 days of an emerging pandemic threat.
- Unresolved risk
- Sustained sovereign funding commitments and resolving international trade barriers during public health emergencies.
Capacity claims quoting hundreds of millions of doses assume bulk mRNA synthesis at standard microgram payloads; sterile fill-finish and cold-chain stability remain binding physical limits.
The optimistic view, with conditions
Manufacturing resilience becomes a portfolio
Regions can build durable capability by pairing routine immunization demand with flexible platforms, interoperable regulation, trained workforces, and emergency options.
Reuse platforms across products
Shared equipment, analytics, and trained teams amortize validated capability across a portfolio, not one product.
Keep demand routine
Pooled procurement and advance commitments keep capacity viable when there is no outbreak to justify it.
Build release capacity alongside reactors
Testing and last-mile logistics need to scale with production, or physical output outruns usable supply.
What durable vaccine supply actually needs
- Recurring demandRoutine immunization programs and pooled procurement that keep capacity used between emergencies.
- Qualified input diversityMultiple pre-approved suppliers for cell banks, lipids, vials, and single-use systems.
- Release-lab capacityTesting infrastructure that scales alongside bioreactors, not behind them.
- Cold-chain reliabilityLogistics that preserve the doses that upstream stages successfully produced.
- Technology transferReal process and quality-system transfer, not just a facility with equipment inside it.
Speed and equitable delivery are different curves
For COVID-19, the first US mRNA vaccine received emergency authorization on 11 December 2020, less than a year after the pathogen emerged. That result depended on prior platform research, at-risk manufacturing and large trials; it is not a generic timeline for a new pathogen. The production surge was measurable: WHO estimates 5.8 billion doses supplied globally in 2019 and about 16 billion in 2021. A later WHO market series records 12.7 billion in 2022 as pandemic volumes fell. Surge capacity is not permanent routine capacity.
Supply was distributed unevenly. In September 2022, WHO reported vaccination rates of 19% in low-income countries versus almost 75% in high-income countries on its cited measure. For HPV vaccine, its market report found introduction in 41% of low-income countries and 83% of high-income countries. The obstacle shifts after the first licensed dose: procurement, fill-and-finish, cold chain, health workers and trust determine whether fast development reaches everyone.
Surge capacity needs a standing market
CEPI's 100 Days Mission is a target for a candidate vaccine against a new threat, not proof that trials, authorization, release and global delivery all fit into 100 days. The WHO lot-release description explains that licensed lots still require review of manufacturer quality results and sometimes national-lab retesting. A generic 14-day sterility incubation is not a universal minimum calendar time for every platform or rapid validated method.
Gavi's African Vaccine Manufacturing Accelerator offers up to $1.2 billion over ten years, with payments linked to eligible products reaching WHO prequalification and commercial supply. A funded factory is not equivalent to released regional doses. BioNTech completed its CureVac acquisition in December 2025; programme listings should treat CureVac as part of that group. Routine immunization requires steady procurement and delivery after pandemic surge lines idle.
Sources, method, and boundaries
Market volume and concentration use WHO's published dataset. The stack distinguishes physical capacity, validated product capability, released supply, and administered access. The interactive yield model uses illustrative, order-of-magnitude stage yields informed by public fill-finish loss literature, not audited figures for any specific product, platform, or manufacturer.
- Drug substance
- The active biological material before formulation into a final dosage form.
- Fill-finish
- Aseptic formulation, filtration, filling, inspection, and packaging of drug substance into final vials or syringes.
- Release testing
- Potency, sterility, and stability testing required before a batch can be distributed.
